PE20140646A1 - Vacuna de virus de dengue inactivado - Google Patents
Vacuna de virus de dengue inactivadoInfo
- Publication number
- PE20140646A1 PE20140646A1 PE2013002709A PE2013002709A PE20140646A1 PE 20140646 A1 PE20140646 A1 PE 20140646A1 PE 2013002709 A PE2013002709 A PE 2013002709A PE 2013002709 A PE2013002709 A PE 2013002709A PE 20140646 A1 PE20140646 A1 PE 20140646A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue virus
- den
- inactivated dengue
- refers
- virus vaccine
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
- 241000725619 Dengue virus Species 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
- 241000710829 Dengue virus group Species 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- UUPHVTQVPXQGSK-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol;methane Chemical compound C.OCN(CO)CO UUPHVTQVPXQGSK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
- 235000011009 potassium phosphates Nutrition 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION INMUNOGENICA DEL VIRUS DE DENGUE QUE COMPRENDE: A) UNO O MAS VIRUS DE DENGUE INACTIVADOS PURIFICADOS DE DIFERENTES SEROTIPOS QUE PROVOCAN UNA RESPUESTA INMUNITARIA A CADA DEN-1, DEN-2, DEN-3 Y DEN-4; B) UN AGENTE REGULADOR TAL COMO FOSFATO DE SODIO, FOSFATO DE POTASIO O TRIS-(HIDROXI-METIL)-AMINO-METANO; C) UN TENSOACTIVO DE POLOXAMERO EN UNA CANTIDAD DE 0.001 A 1% P/V; D) UN ADYUVANTE TAL COMO HIDROXIDO DE ALUMINIO O FOSFATO DE ALUMINIO; Y E) UN COMPONENTE INMUNOESTIMULANTE ADICIONAL TAL COMO UNA EMULSION DE ACEITE Y AGUA, UN LIPOPOLISACARIDO, UNA SAPONINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA PREPARACION LIOFILIZADA DEL VIRUS DE DENGUE INACTIVADO Y A UN METODO DE PREPARACION DEL MISMO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490205P | 2011-05-26 | 2011-05-26 | |
| US201161570966P | 2011-12-15 | 2011-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140646A1 true PE20140646A1 (es) | 2014-05-29 |
Family
ID=46148894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002709A PE20140646A1 (es) | 2011-05-26 | 2012-05-25 | Vacuna de virus de dengue inactivado |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140112953A1 (es) |
| EP (1) | EP2714076A1 (es) |
| JP (1) | JP2014515367A (es) |
| KR (1) | KR20140033171A (es) |
| CN (2) | CN103619349A (es) |
| AU (2) | AU2012260807B2 (es) |
| BR (1) | BR112013030236A2 (es) |
| CA (1) | CA2837145A1 (es) |
| CO (1) | CO6811814A2 (es) |
| EA (1) | EA201391515A1 (es) |
| IL (1) | IL229307A0 (es) |
| MX (1) | MX349119B (es) |
| PE (1) | PE20140646A1 (es) |
| PH (1) | PH12013502442A1 (es) |
| SG (1) | SG194950A1 (es) |
| WO (1) | WO2012160199A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6781508B2 (ja) | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| US10086061B2 (en) * | 2015-03-11 | 2018-10-02 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| JP2018522880A (ja) | 2015-07-02 | 2018-08-16 | プライムヴァックス イミュノ−オンコロジー，インク． | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
| MX2018003757A (es) | 2015-09-26 | 2018-09-21 | Primevax Immuno Oncology Inc | Composiciones y metodos para producir celulas dendriticas. |
| GB201522068D0 (en) * | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
| BE1024160B9 (fr) * | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
| WO2017210215A1 (en) * | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| CA3082779A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
| WO2018129202A1 (en) * | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| CN107140625A (zh) * | 2017-06-14 | 2017-09-08 | 中国海洋大学 | 一种利用植物油制备石墨烯薄膜的方法 |
| AU2018357917B2 (en) | 2017-10-30 | 2024-08-01 | Takeda Pharmaceutical Company Limited | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CA3081581A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
| CA3084605A1 (en) | 2017-11-30 | 2019-06-06 | Takeda Vaccines, Inc. | Method for inactivating zika virus and related methods |
| JP7042341B2 (ja) | 2017-12-07 | 2022-03-25 | メルク・シャープ・アンド・ドーム・コーポレーション | デングウイルスワクチン組成物の製剤 |
| CN114929265A (zh) * | 2019-12-11 | 2022-08-19 | Ne1股份有限公司 | 个性化肿瘤疫苗及其用于癌症免疫疗法的用途 |
| US20240076631A2 (en) * | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| CN112546213A (zh) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法 |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
| CN115531529A (zh) * | 2022-09-16 | 2022-12-30 | 大连理工大学 | 一种冻干保护剂在含铝佐剂中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| NZ525076A (en) * | 2000-10-02 | 2004-09-24 | Glaxosmithkline Biolog S | A split enveloped RSV virus vaccine fomulation |
| DK2236154T3 (en) * | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| EP1766034B1 (en) * | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| CN101679954A (zh) * | 2007-04-06 | 2010-03-24 | 伊维拉根公司 | 用于活的减毒病毒的方法和组合物 |
| US8647643B2 (en) * | 2008-09-29 | 2014-02-11 | Cadila Pharmaceuticals, Ltd | Farnesoid-X-receptor antagonist as a vaccine adjuvant |
| CA2752809A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxosmithkline Biologicals Sa | Inactivated dengue virus vaccine with aluminium-free adjuvant |
| US9005633B2 (en) * | 2009-07-17 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Navy. | Psoralen-inactivated viral vaccine and method of preparation |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2012
- 2012-05-25 CN CN201280031821.0A patent/CN103619349A/zh active Pending
- 2012-05-25 BR BR112013030236A patent/BR112013030236A2/pt not_active Application Discontinuation
- 2012-05-25 PE PE2013002709A patent/PE20140646A1/es not_active Application Discontinuation
- 2012-05-25 US US14/119,902 patent/US20140112953A1/en not_active Abandoned
- 2012-05-25 AU AU2012260807A patent/AU2012260807B2/en not_active Ceased
- 2012-05-25 EP EP12723216.3A patent/EP2714076A1/en not_active Withdrawn
- 2012-05-25 WO PCT/EP2012/059879 patent/WO2012160199A1/en not_active Ceased
- 2012-05-25 CA CA2837145A patent/CA2837145A1/en not_active Abandoned
- 2012-05-25 PH PH1/2013/502442A patent/PH12013502442A1/en unknown
- 2012-05-25 CN CN201710173241.XA patent/CN107050445A/zh active Pending
- 2012-05-25 JP JP2014511908A patent/JP2014515367A/ja active Pending
- 2012-05-25 SG SG2013084298A patent/SG194950A1/en unknown
- 2012-05-25 MX MX2013013862A patent/MX349119B/es active IP Right Grant
- 2012-05-25 KR KR1020137034545A patent/KR20140033171A/ko not_active Ceased
- 2012-05-25 EA EA201391515A patent/EA201391515A1/ru unknown
-
2013
- 2013-11-07 IL IL229307A patent/IL229307A0/en unknown
- 2013-11-26 CO CO13277999A patent/CO6811814A2/es unknown
-
2016
- 2016-08-05 AU AU2016210743A patent/AU2016210743A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL229307A0 (en) | 2014-01-30 |
| AU2016210743A1 (en) | 2016-08-25 |
| AU2012260807B2 (en) | 2016-05-12 |
| CN107050445A (zh) | 2017-08-18 |
| CO6811814A2 (es) | 2013-12-16 |
| US20140112953A1 (en) | 2014-04-24 |
| PH12013502442A1 (en) | 2018-03-21 |
| MX349119B (es) | 2017-07-12 |
| MX2013013862A (es) | 2014-01-23 |
| SG194950A1 (en) | 2013-12-30 |
| KR20140033171A (ko) | 2014-03-17 |
| CA2837145A1 (en) | 2012-11-29 |
| EP2714076A1 (en) | 2014-04-09 |
| CN103619349A (zh) | 2014-03-05 |
| EA201391515A1 (ru) | 2014-05-30 |
| JP2014515367A (ja) | 2014-06-30 |
| BR112013030236A2 (pt) | 2016-12-06 |
| WO2012160199A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| UY35131A (es) | Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4 | |
| MX347210B (es) | Vacunas combinadas para prevención de infecciones por virus porcino. | |
| BR112015001313A2 (pt) | composições de vacina | |
| CO2018011355A2 (es) | Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes | |
| AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| MX374519B (es) | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. | |
| EP2448410A4 (en) | TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS | |
| UY32274A (es) | Pestivirus quimericos | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| MY184428A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| MX2017003117A (es) | Particula tipo virus de flavivirus. | |
| MX2017009306A (es) | Vacuna contra la fiebre aftosa. | |
| BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| CL2013001877A1 (es) | Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
| BRPI0516542A (pt) | composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária | |
| BR112016029201A2 (pt) | vírus do oeste do nilo/dengue quiméricos e métodos de uso | |
| BR112018010690A2 (pt) | vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |